Gattai, Minoli, Partners advised Sofinnova Partners, leading European life sciences venture capital firm based in Paris, London and Milan, in the implementing, through its fund Sofinnova Telethon, a new seed investment in favour of NanoPhoria S.r.l., a pre-clinical stage biotech company that is developing a versatile, non-viral drug delivery platform based on inorganic nanoparticles.